Literature DB >> 10349715

Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis.

P L Worsham1, M R Sowers.   

Abstract

We found that Congo red agar allows identification of sporulation-deficient Bacillus anthracis. Using Congo red agar, we isolated an asporogenic derivative of the protective antigen-producing strain B. anthracis delta Sterne-1(pPA102). Polymerase chain reaction and Southern hybridization analyses of DNA from the asporogenic mutant revealed that a deletion was present in spoOA, an essential gene for the initiation of sporulation. The deletion also encompassed the spoIVB homologue and a portion of the recN homologue. The avirulent spoOA strain delta Sterne-1(pPA102)CR4 is suitable for the safe production of protective antigen without endospore contamination of the vaccine production facility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349715     DOI: 10.1139/cjm-45-1-1

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  11 in total

Review 1.  Occurrence, recognition, and reversion of spontaneous, sporulation-deficient Bacillus anthracis mutants that arise during laboratory culture.

Authors:  Inka Sastalla; Stephen H Leppla
Journal:  Microbes Infect       Date:  2011-11-28       Impact factor: 2.700

2.  Genome engineering in Bacillus anthracis using Cre recombinase.

Authors:  Andrei P Pomerantsev; Ramakrishnan Sitaraman; Craig R Galloway; Violetta Kivovich; Stephen H Leppla
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Microarray analysis of transposon insertion mutations in Bacillus anthracis: global identification of genes required for sporulation and germination.

Authors:  William A Day; Suzanne L Rasmussen; Beth M Carpenter; Scott N Peterson; Arthur M Friedlander
Journal:  J Bacteriol       Date:  2007-02-02       Impact factor: 3.490

4.  Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Authors:  Mark R Deziel; Henry Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Authors:  Arnold Louie; Brian D VanScoy; David L Brown; Robert W Kulawy; Henry S Heine; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

6.  Bacillus anthracis comparative genome analysis in support of the Amerithrax investigation.

Authors:  David A Rasko; Patricia L Worsham; Terry G Abshire; Scott T Stanley; Jason D Bannan; Mark R Wilson; Richard J Langham; R Scott Decker; Lingxia Jiang; Timothy D Read; Adam M Phillippy; Steven L Salzberg; Mihai Pop; Matthew N Van Ert; Leo J Kenefic; Paul S Keim; Claire M Fraser-Liggett; Jacques Ravel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

7.  Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis.

Authors:  J W Farchaus; W J Ribot; S Jendrek; S F Little
Journal:  Appl Environ Microbiol       Date:  1998-03       Impact factor: 4.792

8.  Effect of the Bacillus atrophaeus subsp. globigii Spo0F H101R mutation on strain fitness.

Authors:  Doncho V Zhelev; Mia Hunt; Anna Le; Christopher Dupuis; Suelynn Ren; Henry S Gibbons
Journal:  Appl Environ Microbiol       Date:  2012-10-05       Impact factor: 4.792

9.  Routine markerless gene replacement in Bacillus anthracis.

Authors:  Brian K Janes; Scott Stibitz
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  The secret life of the anthrax agent Bacillus anthracis: bacteriophage-mediated ecological adaptations.

Authors:  Raymond Schuch; Vincent A Fischetti
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.